Myomo to Report Third Quarter Financial Results on November 6, 2024
October 30 2024 - 3:05PM
Business Wire
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a wearable medical robotics company that offers
increased functionality for those suffering from neurological
disorders and upper-limb paralysis, today announced that it will
report financial results for the third quarter ended September 30,
2024 on November 6, 2024.
The Company will host a conference call the same day, Wednesday
November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R.
Gudonis, chairman and chief executive officer, and David Henry,
chief financial officer.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will be given a
conference passcode and unique PIN to gain immediate access to the
call and bypass the live operator. Participants may pre-register at
any time, including up to and after the call start time. Those
without internet access or unable to pre-register may dial in by
calling, 1-844-707-6932 (U.S.) or 1-412-317-9250 (International). A
webcast of the call may also be accessed at Myomo’s Investor
Relations page at https://ir.myomo.com/.
A replay of the webcast will be available beginning
approximately one hour after the completion of the live conference
call at https://ir.myomo.com/. A dial-in replay of the call will be
available until November 20, 2024; please dial 1-877-344-7529 (U.S.
toll free), 855-669-9658 (Canada toll free) or 1-412-317-0088
(International toll) and provide the access code 3377340.
About Myomo, Inc.
Myomo, Inc. is a wearable medical robotics company that offers
improved arm and hand function for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of patients suffering from CVA stroke,
brachial plexus injury, traumatic brain or spinal cord injury or
other neuromuscular disease or injury. It is currently the only
marketed device in the U.S. that, sensing a patient’s own EMG
signals through non-invasive sensors on the arm, can restore an
individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and
reduce their cost of care. Myomo is headquartered in Boston,
Massachusetts, with sales and clinical professionals across the U.S
and representatives internationally. For more information, please
visit www.myomo.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030078888/en/
For Myomo: ir@myomo.com
Investor Relations: Kim Sutton Golodetz Alliance Advisors IR
kgolodtez@allianceadvisors.com 212-838-3777
Myomo (AMEX:MYO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Dec 2023 to Dec 2024